ReviewJournal of extracellular biology2026
Senescent Cell-Derived Extracellular Vesicles in Therapy-Induced Senescence: Immune Remodelling and Emerging Links to Mitochondrial Stress in Cancer.
Review in Journal of extracellular biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer therapy can induce cellular senescence and remodel the tumour microenvironment through the senescence-associated secretory phenotype (SASP), including its membrane-enclosed component, senescent cell-derived extracellular vesicles (senEVs). This review summarizes senEV biogenesis, cargo-dependent functions, and immune-remodelling effects while distinguishing mechanisms directly demonstrated in experimentally validated senescent-cell EV models from contextual evidence derived from broader EV and mitochondrial-stress studies. Direct evidence shows that senEVs can support immune-mediated clearance in some models or promote tumour growth, chemoresistance, and polymorphonuclear myeloid-derived suppressor cell (PMN-MDSC)-mediated immunosuppression in others. We further evaluate mitochondrial stress and EV-associated mitochondrial DNA as an emerging mechanistic framework that may contribute to these divergent outcomes, rather than as an established general regulator of senEV activity. Finally, we discuss candidate intervention strategies, evidence gaps, and the experimental requirements needed to define how donor-cell state, cargo composition, recipient-cell identity, treatment context and time after treatment may shape senEV function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.